Last reviewed · How we verify
DE-117
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | DE-117 |
|---|---|
| Sponsor | Santen Inc. |
| Drug class | Rho kinase (ROCK) inhibitor |
| Target | ROCK1/ROCK2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ROCK inhibitors modulate the cytoskeleton and cell contractility in ocular tissues, particularly enhancing conventional outflow facility in the eye. By inhibiting ROCK signaling, DE-117 increases the relaxation of trabecular meshwork cells and endothelial cells lining Schlemm's canal, thereby facilitating drainage of aqueous humor and lowering intraocular pressure. This mechanism differs from prostaglandin analogs and beta-blockers, offering a novel approach to glaucoma management.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Blurred vision
Key clinical trials
- A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT (PHASE3)
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study (PHASE3)
- DE-117 Spectrum 5 Study (PHASE3)
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study (PHASE3)
- Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 (PHASE2)
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT (PHASE1, PHASE2)
- Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-117 CI brief — competitive landscape report
- DE-117 updates RSS · CI watch RSS
- Santen Inc. portfolio CI